Open access

Role of Crystallization in Genesis of Diverse Crystal Forms of Antidiabetic Agents

Written By

Renu Chadha, Dimpy Rani and Parnika Goyal

Submitted: 30 June 2014 Published: 06 May 2015

DOI: 10.5772/59674

From the Edited Volume

Advanced Topics in Crystallization

Edited by Yitzhak Mastai

Chapter metrics overview

3,412 Chapter Downloads

View Full Metrics

1. Introduction

Crystallization is a crucial step in the manufacturing and processing of active pharmaceutical ingredients (API’s) in pharmaceutical industry [1]. As crystallization is coupled with molecular recognition, a slight alteration in crystallization conditions can affect crystal and powder properties accompanied with thermodynamic and mechanical properties [2]. So, the selection of an appropriate solid form of an active pharmaceutical ingredient (API) in the early stages of drug development is very important as it can be pure crystalline form or its non covalent modification such as polymorph, amorphate, hydrate, solvate, salt or co-crystals exhibiting unique physicochemical properties (solubility, dissolution rates, stability and bioavailability) and other performances characteristics of drug [3].

Existence of a crystalline solid into many crystalline forms leads to polymorphism which is a phenomenon, hard to predict. It may be of two types either conformational (due to existence of various conformers of molecule) or packing polymorphism (due to difference in crystal packing). On thermodynamic consideration, there are also two types of polymorphism i.e., monotropic system (when the transition of one form to another is irreversible) and enantiotropic system (reversible forms) [4]. In general, least stable crystal form crystallizes out first, not the most stable form. Metastable crystal form (unstable) tend to change to more stable from under particular conditions [5]. Crystal forms are the entities which are similar at molecular level but dissimilar in supramolecular aspect [6].

The various conditions used in the process of crystallization is the chief cause of generation of different crystal forms of a molecule and the difference in the properties of various crystal forms is due to different crystal packing and lattice energy [4]. Advancement in synthesis has gained control on the synthesis and purity of drugs but still lag behind in controlling the crystallinity and physical crystal forms. Different forms of a crystalline solid can be controlled by controlling the crystallization process.

The best method used for obtaining the variety of crystal forms is crystallization as it is traditional, easy and unbeatable process. Crystallization techniques may be solvent or non-solvent based and varied methods give rise to different forms. Solvent crystallization techniques include solvent evaporation, slow cooling of the solution, diffusion, vapour diffusion while non solvent techniques include sublimation, thermal treatment, desolvation of solvates, grinding and crystallization from melt etc. The choice of appropriate technique may be decided depending on the amount of sample and physical stability or solubility of drug [7-8].

Different crystal forms due to different crystal lattice have different physicochemical properties and thus therapeutic effects. Thus, Pharmaceutical companies usually search for a crystal form or polymorph with the best properties for therapeutic use and manufacturability. Selection of an optimized crystal form is of more relevance as regulatory bodies are showing their interest in physico-chemical characterization of APIs. Polymorphism is also important to be considered because this phenomenon is not exhibited by only drug molecule but also by other solid forms prepared by drug using crystal engineering approaches like salts, solvates, co-crystals etc. However, the discovery and genesis of various crystal forms is quite tiresome and expensive [9-12].

This chapter has focused on the various crystal forms of anti-diabetic agents and techniques employed in their preparation.

Diabetes mellitus is an unceasing disease in the society that requires life-long pharmacological and non-pharmacological management. Among this, type 2 diabetes mellitus is more prevalent. For the management of type 2 diabetes mellitus, various oral agents have been approved. The main problem of these agents is their dissolution limited bioavailability. To overcome this issue various attempts like CD complexes, solid dispersion, crystal engineering approaches and exploring the more soluble polymorphic form have been made.


2. Case studies of crystal forms of antidiabetics

Several crystalline forms of anti-diabetics have been described in the past. A general account of different crystal forms, their method of preparation along with transition / melting temperature are detailed in table 1.


3. Sulfonyluraeas

3.1. Acetohexamide

Potentiality of polymorphism in acetohexamide was first observed by Girgis-Takla and Chroneos in 1977. They reported two polymorphic forms (polymorphs A and B), distinguished by IR spectra and further characterized by Mueller and Lagas. However, forms showed no notable differenceon drying at 60°C in vaccum [13-14]. Graf et al. proposed keto-enoltautomerism for their stability, confirmed by IR spectra. Polymorph A (enol form) forms six membered ring via bonding of an O—H and S=O group intramolecularly while polymorph B (keto form) shows intermolecular bonding of C=O of urea to a sulphonamide N—H [15-16].

Kuroda et al. collected three crystal forms (Form I, Form II and CHCl3 – II) out of which one was found to be chloroform solvate. Form II was found to be 1.2 times more soluble than Form I [17].Yokoyama et al. estimated the thermodynamic values (transition temperature - 154°C & heat of transition - 230°C) of crystal forms (Form I and Form II) from solubility studies. Both forms were found equally bioavailable inbeagle dogs [18].Another forms Form IV by Graf et al and Form II and III by Al-Saieq and Rileywere investigated [19-20]. Later Graf et al. found that Form II was mixture of I and IV, while Form III (by Al-Saieq and Riley) on heating, converted to a new polymorph V [15].

Another crystal form of acetohexamide (Form VI) by Aldawsariet al. was reportedand was more soluble in water, and more bio-available in rats as compared to other already reported crystal forms [21].

3.2. Chlorpropamide

Various publications on the crystal forms (about 16) of chlorpropamide were reported (by Simmons et al., Burger et al., and Saieq et al.)[22-24], but the provided data could not distinguish existing crystal forms in actual [1-3]. Ueda et al. depicted convex shaped dissolution curve for Form C (by simmons et al.) and Form II (by saieq et al.)that indicates crystallization along with anhydrate to hydrate phase transformation [25].

After that, Debrushchaket al. adopted a new methodology for nomenclature (α, β, γ, δ, ε) on the basis of the order of their crystal structure established. Form α, β, γ and δ correspond to previously reported Form III, II, IV and VI respectively and was found that all forms transformed to ε (Form I) crystal form.On cooling up to 200 K, crystal form ε, converted to another new form (ε’). This new form resembled to α form in aspect of cell parameters and molecular conformation while to ε form in case of packing (Z shaped ribbons). Form α, β, γ has same intermolecular hydrogen bonding but differ in packing and number of molecules in unit cell [26-30].

Bifurcated intermolecular hydrogen bonding pattern of carbonyl group has been seen with the two amine hydrogen atoms, and SO2 oxygen atom acquires hydrogen from the nitrogen attached to alkyl tail.With regard to enthalpy of transition, conversion of α, β, γ and δ to ε should be in order of β > γ > δ > α but β polymorph infracts it because of structural difference [31].

All these polymorphs are conformational polymorphs as they showed difference in torsion angles. (as shown in figure 1) [32]

Figure 1.

Chlorpropamide with possible torsion angles [32]

Process of crystallization was also found to be affected by the presence or absence of 2-hydroxybutyl-β-cyclodextrin as chlorpropamide crystallized to metastable Form II and III in presence, whereasto Form A in the absence at 4C. Even the appearance of crystal form was dependent on the concentration and temperature [33].

3.3. Tolbutamide

Several Tolbutamide polymorphs are reported by several groups of workers. [34-42]. Two forms reported by Simmons et al[34] (Forms A and B) are identical with the Burger’s Form I and III [35], respectively, and have been well characterized. However, Burger’s Forms II and IV have been not fully characterized.

3.4. Glimepiride

Two polymorphs (Form I and II) are reported in literature. New crystalline form (Form II) was prepared by recrystallization from an ethanol/water system was found to have different dissolution profile and solubility [43] and it transformed to Form I over 140°C.

3.5. Glibenclamide

Crystallisation of glibenclamide from different solvents and quick cooling of melt gave three polymorphic forms and pseudopolymorphs (solvates), which were significantly different with regard to solubility and melting properties. [44-45] A new crystalline form of glibenclamide,with higher melting point (218°C) and lower solubility, was formed during an attempt to elucidate transitional phases by melting, cooling and reheating by A. Panagopoulou-Kaplani, et al[46].


4. Meglitinides

4.1. Nateglinide

Various solvates/ hydrates (about 26) of nateglinide have been patented which eventually converts to either Form B or Form H. [47] The S polymorph was crystallized from the melt or by isothermal treatment of B or H forms at temperatures higher than their melting points which is the only stable form, while the polymorphs B and H are metastable forms. The anhydrous polymorph, if stored at room temperature and humidity, gradually changes to H polymorph while, if stored in water vapour saturated atmosphere, it gets back water and reverts to the hemihydrate form. On the contrary, both an isothermal treatment at 80 ◦C and melt cooling bring to the B polymorph [48].

4.2. Repaglinide

S enantiomer of repaglinide was found active hypoglycemic agent andthree crystalline forms (Form I, II and III) were crystallized from various solvents by solvent/antisolvent and slow evaporation method. Form II (low melting crystal form) on further heating showed second melting endotherm at 127-130°C and converted to Form I if crystallized in ethanol/water mixture [49].


5. Biguanides

5.1. Metformin hydrochloride

Two polymorphs (form A and B) has been identified out of which form A is more thermodynamically more stable while highly metastable structure, which correlates with the difficulty in handling this polymorph [50]. These two polymorphs and their mixture has been evaluated by Scott L. Childs, et al using capillary crystallization and thermal microscopy techniques. Crystal structure of these forms arereported [51]. Both structures are monoclinic (P21/c) with one complete metformin cation and one chloride anion in the asymmetric unit as shown in figure 2.

Figure 2.

Metformin hydrochloride Form A and B shown, respectively at 50% probability ellipsoids. [50]


6. Thiazolididiones

6.1. Rosiglitazone

Various crystalline forms of maleate salt of rosiglitazone are reported in literature. Choudary et al. and Blackler et al. put illumination on crystalline hydrates of salt [52-54]. Chebiyyam et al. described four crystalline forms (Form I, II, III and IN) while Birari et al. described two forms (Form A and B). Form A was detected more stable than B and all the other crystal forms, amorphous form, hydrate and anhydrate converted to Form A [55-56]. Kansalet al. depicted three crystal forms (Form I, III and IV) for hydrobromide salt of rosiglitazone and formulated Form III in compacted dosage form, while Greil et al. elaborated two hydrates (Form A and C), one solvate (Form D) and three anhydrate (Form B, B1 and E). 1:1 hydrates were recovered which may lose their water content at different temperature. Form B and B1 have shown same melting endotherm temperature but they were distinguished by PXRD [57-58].

6.2. Pioglitazone hydrochloride

Only two polymorphic form I and II has been evaluated which are patented [59].

6.3. Troglitazone

Various crystalline forms of troglitazone are patented. Polymorphs 1,2,3 and 6 are obtained by different modes of recrystallization while form 4 and 5 are derived by heating any one of the form 1, 2, 3 or 6 [60].


7. Dipeptidyl peptidase-4 inhibitor

7.1. Alogliptin

In literature, six crystal forms of tartrate (Form A, B, C, D, E and F) and one crystalline form of benzoate salt of alogliptin (Form A) were reported. Among the crystal forms of alogliptin tartrate, Form A was found to be more stable and all forms during stability studies converted to Form A. The most stable form were analyzed for solubility and alsoestablished thermally stable up to 200°C and a variable hydrate.

Form A of benzoate salt was found to be much stable and amorphous form converted to stable Form A during heating [61-62].

7.2. Linagliptin benzoate

Crystalline forms of linagliptin benzoate have been patented. Form II is less hygroscopic then Form I. Thus, can be easily handled in standard pharmaceutical processing conditions and no special packing is required during its storage [63].

7.3. Sitagliptin

Numerous solvates and crystal forms of sitagliptin phosphate have been patented. All the reported crystalline solvates converted to Form II on desolvation and on heating metastable Form II converted to Form I (at 45°C) and to Form III at 110°C. Form I (stable at higher temperature) and Form III (stable at lower temperature) have enantiotropic relation [64]. Form IV, also a metastable form, slowly converted to crystalline sitagliptin phosphate monohydrate [65]. Huang et al. prepared Form V and processed them to pharmaceutical formulation [66].

7.4. Saxagliptin

Monohydrate, hemihydrates and mixture of thereof of saxagliptin had been prepared and patented [67].Nine polymorphic forms of saxagliptin hydrochloride (Form K, T, Z, N, S, O, B, C and D) had been evaluated either from its amorphous form or dihyrate form and being patented. Forms K, S, N and Z are polymorphically pure, Form D is a hydrate, Form T is in a mixture with ammonium chloride, Form O is in a mixture with form K and saxagliptinmonochydrochloridemonohydtare while Form B is in a mixture with saxagliptinmonochydrochloridedihyrate [68]

Table 1.

Crystalline Forms of Antidiabetics


8. Conclusion

The crystallization process has profound impact on crystal forms, which further affect biopharmaceutical properties of pharmaceutical solids. Various crystal forms of antidiabetics have been reported in literature and some have even gained the status of a patent. The existence of these different crystal forms are possible due to presence of sulphoxamide, carboxamide, thiazolidendione, etc. groups in these agents. For the optimized pharmaceutical acceptable solid form, one must be cognizant of the potentiality of an API to exist in various crystal forms by altering the crystallization conditions. Because of this, screening of new crystal forms of API’s has become a vital part of drug discovery and development in past decade.



Authors are grateful to Council of Scientific and Industrial Research, New Delhi for their financial support under project scheme 02(0039)/11/EMR-II.


  1. 1. Chen J, Sarma B, Evans JMB, Myerson AS. Pharmaceutical Crystallization. Crystal Growth & Design 2011;11:887-895.
  2. 2. Doherty R. The Application of Computational Chemistry to The Study of Molecular Materials. In: Myerson AS, Green D, Meenan P. (ed.) Crystal Growth of Organic Materials. Washington DC: American Chemical Society; 1996. p2–14.
  3. 3. Byrn SR, Pfeiffer RR, Stowell JG. Solid-State Chemistry of Drugs. West Lafayette: SSCI; 1999.
  4. 4. Grant DWJ. Theory and Origin of Polymorphism. In: Brittain HG. (ed.) Polymorphism In Pharmaceutical Solids. New York: Marcel Dekker, Inc. p1-34.
  5. 5. Ostwald W. StudienÜber Die Bildnung Und Umwandlung Fester Körper.ZeitschriftFürPhysicalischeChemie 1896;22 289–330.
  6. 6. Desiraju GR. Polymorphism: The Same and Not Quite the Same. Crystal Growth & Design 2008;8(1):3-5.
  7. 7. Guillory JK. Generation of Polymorphs Hydrates Solvates and Amorphous Solids. In: Brittain HG. (ed.) Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, Inc. p183–226.
  8. 8. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, CimaMJ,Gardner CR. High-Throughput Crystallization: Polymorphs, Salts, Co-Crystals and Solvates of Pharmaceutical Solids. Advance Drug Delivery Review 2004;56:275–300.
  9. 9. FDA Pharmaceutical cGMPs for the 21st Century – A Risk Based Approach.U.S. Food andDrug Administration; 2004a.
  10. 10. FDA Process Analytical Technology (PAT) – A Framework For Innovative PharmaceuticalDevelopment Manufacturing And Quality Assurance.U.S. Food and Drug Administration; 2004b.
  11. 11. ICH Q8 Pharmaceutical Development.International Conference on Harmonization; 2005a.
  12. 12. ICH Q9 Quality Risk Management.International Conference on Harmonization; 2005b.
  13. 13. Girgis-Takala P, Chroneos I. The Polymorphism of Acetohexamide. Journal of Pharmacy and Pharmacology 1977;29(10):640-642
  14. 14. Müller B, Lagas M. Some aspects of the polymorphism and stability of acetohexamide.PharmaceutischWeekblad 1979;1(1):449-56.
  15. 15. Graf E, Bayer C, Abdallah O. On The Polymorphism of Acetohexamide. Pharm Ind 1984;46:955-959.
  16. 16. Takla P, Dakas CJ. An infrared study of tautomerism in acetohexamide polymorphs. Journal of pharmacy and pharmacology 1989;41(4):227-30.
  17. 17. Kuroda K, Yokoyama T, Umeda T, Takagishi Y. Studies on Drug Nonequivalence. VI. Physicochemical Studies on Polymorphism of Acetohexamide. Chemical and Pharmaceutical Bulletin 1978;26(8):2565-2568.
  18. 18. Yokoyama T, Umeda K, Kuroda K. Sato K, Takagishi Y. Studies on Drug Nonequivalence. VII. Bioavailability of Acetohexamide Polymorphs. Chemical and Pharmaceutical Bulletin 1979;27(6):1476-1478.
  19. 19. Graf E, Beyer C, Abdallah O. PolymorphiebeiAcetohexamid. ActaPharmaceutica Technology 1979;25:9-20.
  20. 20. Al-Saieq, S.S., Riley, G.S.Polymorphism in sulfonylurea hypoglycemic agents. III. Acetohexamide. PharmaceuticaActa Helvetiae1982;57:43–46.
  21. 21. Aldawsari H, Altaf A, Banzar ZM, Lohara D, Nakabayashi M, Anraku M. Crystallization of A New Polymorph of Acetohexamide from 2-Hydroxybutyl-β-cyclodextrin Solution: Form VI with A High Aqueous Solubility. International Journal of Pharmaceutics 2013;453(2):315-321.
  22. 22. Simmons DL, Ranz RJ, Gyanchandani ND. Polymorphism in pharmaceuticals. II. Chlorpropamide. Canadian Journal of Pharmaceutical Sciences 1973;8(4):125-127.
  23. 23. Burger A. ZurPolymorphieoralerAntidiabetika.ScientiaPharmaceutica 1975;43:152-161
  24. 24. Aal-Saieq SS, Riley GS. Polymorphism in sulfonylurea hypoglycemic agents, II: chlorpropamide. PharmaceuticaActaHelvetiae 1982;57(1):8-11.
  25. 25. H. Ueda, N. Nambu and T. Nagai, Dissolution behavior of chlorpropamide polymorphs. Chemical & pharmaceutical bulletin 1984;32(1):244-50.
  26. 26. Koo CH, Cho SI, Yeon YH. The crystal and molecular structure of chlorpropamide. Archives of Pharmacal Research 1980;3(1):37-49.
  27. 27. Drebushchak TN, Chukanov NV, Boldyreva EV. A new polymorph of chlorpropamide: 4-chloro-N-(propylaminocarbonyl) benzenesulfonamide. ActaCrystallographica Section E: Structure Reports Online 2006;62(10):o4393-o4395.
  28. 28. Drebushchak TN, Chukanov NV, Boldyreva EV. A new-polymorph of chlorpropamide: 4-chloro-N-(propylaminocarbonyl) benzenesulfonamide. ActaCrystallographica Section C: Crystal Structure Communications 2007;63(6):o355-o357.
  29. 29. Drebushchak V, Drebushchak TN, Chukanov N, Boldyreva EV. Transitions among five polymorphs of chlorpropamide near the melting point. Journal of Thermal Analysis and Calorimetry 2008;93(2):343-351.
  30. 30. Drebushchak TN, Chukanov NV, Boldyreva EV. Two polymorphs of chlorpropamide: the-form and the high-temperature-form. ActaCrystallographica Section C: Crystal Structure Communications 2008;64(12):o623-o625.
  31. 31. Drebushchak TN, Chesalov YA, Boldyreva EV. A conformational polymorphic transition in the high-temperature-form of chlorpropamide on cooling: a new'-form. ActaCrystallographica Section B: Structural Science 2009;65(6):770-781.
  32. 32. Ayala A, Caetano M, Honorato S, Mendes Filho J, Siesler H, Faudone S, et al. Conformational polymorphism of the antidiabetic drug chlorpropamide. Journal of Raman Spectroscopy 2012;43(2):263-272.
  33. 33. Ishiguro T, Hirayama F, Iohara D, Arima H, Uekama K. Crystallization and polymorphic transitions of chlorpropamide in aqueous 2-hydroxybutyl-β-cyclodextrin solution. European Journal of Pharmaceutical Sciences 2010;39(4):248-55.
  34. 34. Simmons DL, Ranz RJ, Gyanchandani ND, Picotte P. Polymorphism in pharmaceuticals II (tolbutamide). Canadian Journal of Pharmaceutical Sciences 1972;7:121-123.
  35. 35. Burger A. Zurpolymorphieoralerantidiabetika.ScientiaPharmaceutica 1975;43:161-168.
  36. 36. Burger A, Ramberger R. On the polymorphism of pharmaceuticals and other molecular crystals. II. Applicability of thermodynamic rules. MikrochimicaActa 1979:273-316.
  37. 37. Al-Saieq SS, Riley GS. Polymorphism in sulphonylurea hypoglycaemic agents: I. Tolbutamide. PharmaceuticaActaHelvetiae 1981;56:125-129.
  38. 38. Leary JR, Ross SD, Thomas MJK. On characterization of the polymorphs of tolbutamide. Pharmaceutisch Weekblad, Scientific Edition 1981;3:62-66.
  39. 39. Umeda T, Ohnishi N, Yokoyama T, Kuroda T, Kita Y, Kuroda K, Tatsumi E, Matsuda Y. A kinetic study on the isothermal transition of polymorphic forms of tolbutamide and mefenamic acid in the solid state at high temperatures. Chemical and Pharmaceutical Bulletin 1985;33:2073-2078.
  40. 40. Traue J, Kala H, Ko°hler M, Wenzel U, Wiegeleben A, Fo°rster B, Pollandt P, Pintye-Ho´di K, Szabo´-Re´ve´sz P, Selmeczi B. Untersuchungenzurpolymorphie von arzneistoffen in pulvern und tabletten. Pharmazie 1987;42:240-241.
  41. 41. Georgarakis M. Untersuchungenzurpolymorphie von tolbutamid.Pharmazie 1989;44:209-210.
  42. 42. Olives AI, Martin MA, del Castillo B, Barba C. Influence of the presence of trace amounts of metals on the polymorphism of tolbutamide. International Journal of Pharmaceutics 1996;14:1069- 1076.
  43. 43. Endo T, Iwata M, Nagase H, Shiro M, Ueda H. Polymorphism of glimepiride: Crystallographic study, thermal transitions behavior and dissolution study. STP Pharma Sciences 2003;13(4):281–286.
  44. 44. Suleiman MS, Najib NM. Isolation and physicochemical characterization of solid forms of glibenclamide International Journal of Pharmaceutics 01/1989; DOI: 10.1016/0378-5173(89)90134-8.
  45. 45. Hassan MA, Salem MS, Sallam E, Al-Hindawi M.K. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. ActaPharmaceuticaHungarica 1997;7:81–88.
  46. 46. Panagopoulou-Kaplani A, Malamataris S. Preparation and characterisation of a new insoluble polymorphic form of glibenclamide. International Journal of Pharmaceutics 2000;195:239–246.
  47. 47. Wizel S, Frenkel G, Gome B. Polymorphic forms of Nateglinide. US patent 2006/0004102 A1, 2006.
  48. 48. Brunia G, Berbennia V, Milanesea C, Girellaa A, Cardinib A, Lanfranconib S, Marinia A.New solid modifications of nateglinide Journal of Pharmaceutical and Biomedical Analysis2010;51:1054–1059.
  49. 49. Reddy MS, Eswaraiah S, Trippapnchar MV, Shanmugam G, Madhavi M, Kumar KN.Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof. US Patent20,040,102,477; 2004.
  50. 50. Scott LC, Leonard JC, Jeanette TD, David AC, Barbara CS, Patrick Stahly G. A Metastable Polymorph of Metformin Hydrochloride: Isolation and Characterization Using Capillary Crystallization and Thermal Microscopy Techniques Crystal Growth & Design 2004; 4(3):441-449.
  51. 51. Hariharan M, Rajan SS, Srinivasan R. ActaCrystallographica Section C: Crystal Structure Communication 1989;45:911-913.
  52. 52. Choudary BM, Lynch IR, Sasse MJ, Plc SB. Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use. PCT/EP1998/008153(Date:1999-06-24)
  53. 53. Blackler PD, Lee DC, Sasse MJ, Plc SB.Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt. PCT/EP1998/008154(Date:1999-06-24)
  54. 54. Blackler PD, Lee DC, Sasse MJ, Plc SB 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical. PCT/EP1998/008155(Date:1999-06-24)
  55. 55. Chebiyyam P, Gaddam OR, Krishnamurthi V, Mamillapalli RS, Seella VR. Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation.US PatentApplication No. PCT/US2001/029896(Date: 2002-04-4)
  56. 56. Birari DR, Kankan RN, Phull MS, Rao DR. Process for the production of polymorphs of rosiglitazone maleate. US Patent Application No. PCT/GB2004/003519(Date: 2005-03-10)
  57. 57. Kansal VK, Nayal S, Rafilovich M, Ranjan H. Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation. Google Patents; Patent Application No. 12/583,509, (Date:2009-03-25).
  58. 58. Greil J, Ludescher J, Wolf S. Rosiglitazone Phosphate and Polymorphic Forms. Google Patents Application No. PCT/EP2005/001378(Date:2005-2-11).
  59. 59. Shlomit Wizel, Serguei Finogueev, Jean Hildesheim Pioglitazone Hydrochloride. US patent 2003/0139603 A1, 2003.
  60. 60. Krishnamurthi Vyas; Chebiyyam Pmbhakar; Smelling Dhamaraja Rao; Mamillapalli Ramabadhra,Sarina; Om Gaddam Reddy; Rajagopalan Ramanujam; Chakrabarti, Polymorphic Forms of Troglitazone Having Enhanced anti-Diabetic Activity and a Process for their Preparation. US patent 005700820A, 1997.
  61. 61. Leonard J. Chyall, Lafayete, Keith Lorimer, Linda J, Mcclausland. Polymorphs of Tartrate Salt of 2-[2-(3-(R)-Amino-Piperidin-1-Yl)-5-Fluoro-6-Oxo-6h-Pyrimidin-1ylmethyl]-Benzonitrile and Methods of Use Therefore (US 2007/0066636). Application No.: 11/531,638. (Date: 2007-03- 22).
  62. 62. Marom E, Rubnov S. Polymorphs of Alogliptin benzoate. Google Patents;US Patent Application. 13/697,455. (Date:2012-11-12).
  63. 63. Sandoz AG Hotter, Andreas, Pichler, Arthur Polymorph of Linagliptin Benzoate International Publication No. WO/2012/152837, (Date: 15.11.2012).
  64. 64. Robert MW, Joseph DA, Chen AM, Cypes S, Russell R. Ferlita, KH, Christopher L, Evangelia S. Novel Crystalline Forms Of A Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor. PCT/US04/27983(Date:2006-12-21)
  65. 65. Chen AM, Wenslow RM. Novel Crystalline Form of a Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor. PCT/US2004/030434(Date: 2004-09-17)
  66. 66. Huang CG, Huang MH. Crystalline Polymorph of Sitagliptin Phosphate and Its Preparation.US Patent. US 2009/0247532 A1(Date: 2009-10-01).
  67. 67. Marina Ratkaj, TomislavBilj an, Marina Marinkovic, Saxagliptin Intermediates,Saxagliptin Polymorphs andProcesses for Preparation Thereof US Patent No. 8,501,960 B2, 2013.
  68. 68. Marina Marinkovic,Marina Ratkaj, Oliver Frankovic, Tina Mundorfer. Polymorphs of Saxagliptin Hydrochloride And Processes for Preparing Them. US Patent No. 2013/0158091 A1, 2013.
  69. 69. Naba KN, Ashwini N. Novel form V of tolbutamide and a high Z’ crystal structure of form III Crystal Engineering Communication 2011;13:47.
  70. 70. Rudy B, Sumaia AP, Leonardo MBF, Ade´Lia E. De Almeida Antoˆ Nio C. Doriguetto MB, De Arau´ Jo, He´Rida RNS. A Discriminating Dissolution Method for Glimepiride Polymorphs Journal Of Pharmaceutical Sciences 2012;101(2):794-804.
  71. 71. Michito S, Yoshihito K, Takao O, Yasuo I, Satoji Takahashi, Yottukaichi, Methods For Producing Nateglinide B-Type Crystals. US Patent No. 7,544,834 B2, 2009.

Written By

Renu Chadha, Dimpy Rani and Parnika Goyal

Submitted: 30 June 2014 Published: 06 May 2015